Jabil’s AI Revenue Is Set to Surge 50%. UBS Says It’s Time to Buy.

Roche's experimental eye drug shows vision improvements in trials

The S&P 500 Just Hit a Record High -- Here's How Much Higher It Can Climb, According to the Wall Street Consensus

Global equities mixed amid rising yields and oil prices

Merck's experimental eye drug meets goal in trial, but raises safety concerns